Deerfield Management Company, L.P. (Series C) Dyne Therapeutics, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 435,653 shares of DYN stock, worth $12.4 Million. This represents 0.29% of its overall portfolio holdings.
Number of Shares
435,653Holding current value
$12.4 Million% of portfolio
0.29%Shares
7 transactions
Others Institutions Holding DYN
# of Institutions
210Shares Held
102MCall Options Held
234KPut Options Held
238K-
Atlas Venture Life Science Advisors, LLC8.02MShares$228 Million35.54% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$210 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.86MShares$195 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY6.82MShares$194 Million3.9% of portfolio
-
Janus Henderson Group PLC London, X06.81MShares$193 Million0.13% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.47B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...